Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154
NCT ID: NCT00535834
Last Updated: 2012-03-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
48 participants
OBSERVATIONAL
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying samples collected from patients with localized prostate cancer who received treatment on clinical trial NCI-00-C-0154.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer
NCT00003871
A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate
NCT00001382
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
NCT02933255
Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)
NCT00005039
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
NCT02326805
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Evaluate the formation of antibody complexes in serum samples taken before initiation of treatment and after completion of therapy in prostate cancer patients previously enrolled on clinical trial NCI-00-C-0154.
* Evaluate immunologic response.
Secondary
* Clone the underlying tumor antigens discovered through SEREX.
OUTLINE: Samples previously collected on clinical trial NCI-00-C-0154 (whole blood, serum, and peripheral mononuclear blood cells) are analyzed for immunologic responses and evidence of formation of anti-tumor antibodies. Western blot is used to detect any evidence of vaccine-induced autoantibody responses. If there is an indication of response, SEREX is used to clone the underlying antigens.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
diagnostic procedure
molecular diagnostic method
protein expression analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of localized adenocarcinoma of the prostate
* Received treatment on clinical trial NCI-00-C-0154
PATIENT CHARACTERISTICS:
* Consented the use of their collected blood cells for future research while enrolled on NCI-00-C-0154
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
National Institutes of Health Clinical Center (CC)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James Gulley, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-C-N214
Identifier Type: -
Identifier Source: secondary_id
CDR0000565972
Identifier Type: -
Identifier Source: secondary_id
999907214
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.